Legislative Research: NJ A2830 | 2020-2021 | Regular Session

Other Sessions

SessionTitle/DescriptionLast Action
2024-2025
Regular Session

(Introduced)
Authorizes common law public nuisance suits regarding lead paint under State law; exempts Attorney General from certain aspects of public nuisance claims when pursuing lead paint actions.
[A2830 2024 Detail][A2830 2024 Text][A2830 2024 Comments]
2024-01-09
Introduced, Referred to Assembly Environment, Natural Resources, and Solid Waste Committee
2022-2023
Regular Session

(Introduced - Dead)
Regulates dental therapy and licensure of dental therapists.
[A2830 2022 Detail][A2830 2022 Text][A2830 2022 Comments]
2022-02-28
Introduced, Referred to Assembly Regulated Professions Committee
2020-2021
Regular Session

(Introduced - Dead)
Requires health benefits coverage for buprenorphine and buprenorphine/naloxone for pain treatment without step therapy or fail-first protocols.
[A2830 2020 Detail][A2830 2020 Text][A2830 2020 Comments]
2020-02-20
Introduced, Referred to Assembly Financial Institutions and Insurance Committee
2018-2019
Regular Session

(Introduced - Dead)
Clarifies law governing appointment of freeholder as county counsel or county treasurer.
[A2830 2018 Detail][A2830 2018 Text][A2830 2018 Comments]
2018-02-01
Introduced, Referred to Assembly State and Local Government Committee
2016-2017
Regular Session

(Introduced - Dead)
Requires DCA to adopt energy inspection code, and requires licensed home inspector to report energy analysis for each home inspected for buyer in contemplation of purchase.
[A2830 2016 Detail][A2830 2016 Text][A2830 2016 Comments]
2016-02-16
Introduced, Referred to Assembly Housing and Community Development Committee
2014-2015
Regular Session

(Introduced - Dead)
Requires notification to Division of Child Protection and Permanency upon arrest of child's primary caregiver.
[A2830 2014 Detail][A2830 2014 Text][A2830 2014 Comments]
2014-03-10
Introduced, Referred to Assembly Human Services Committee
2012-2013
Regular Session

(Introduced - Dead)
"Opportunity Scholarship Act"; establishes pilot program in Department of Treasury providing tax credits to entities contributing to scholarships for low-income children; appropriates $1,500,000 to Treasury.
[A2830 2012 Detail][A2830 2012 Text][A2830 2012 Comments]
2012-05-10
Introduced, Referred to Assembly Education Committee
2010-2011
Regular Session

(Introduced - Dead)
Allows bureau chief to assess civil penalty for certain violations of "Uniform Securities Law (1997)."
[A2830 2010 Detail][A2830 2010 Text][A2830 2010 Comments]
2010-06-10
Introduced, Referred to Assembly Law and Public Safety Committee

References Online

Search PhraseWebNewsFinancialEncylopediaBiography
[New Jersey A2830]Google WebGoogle News
[New Jersey Assembly Financial Institutions and Insurance Committee]Google WebGoogle NewsFollowTheMoney
[Representative Carol Murphy NJ]Google WebGoogle NewsFollowTheMoneyBallotpediaVoteSmart
[Representative Valerie Huttle NJ]Google WebGoogle NewsFollowTheMoneyBallotpediaVoteSmart
[Representative Annette Chaparro NJ]Google WebGoogle NewsFollowTheMoneyBallotpediaVoteSmart

Legislative Citation

APA
NJ A2830 | 2020-2021 | Regular Session. (2020, February 20). LegiScan. Retrieved May 05, 2024, from https://legiscan.com/NJ/bill/A2830/2020
MLA
"NJ A2830 | 2020-2021 | Regular Session." LegiScan. LegiScan LLC, 20 Feb. 2020. Web. 05 May. 2024. <https://legiscan.com/NJ/bill/A2830/2020>.
Chicago
"NJ A2830 | 2020-2021 | Regular Session." February 20, 2020 LegiScan. Accessed May 05, 2024. https://legiscan.com/NJ/bill/A2830/2020.
Turabian
LegiScan. NJ A2830 | 2020-2021 | Regular Session. 20 February 2020. https://legiscan.com/NJ/bill/A2830/2020 (accessed May 05, 2024).

Subjects


Same As/Similar To

BillRelationshipDateTitleLast Action
A2544Carry Forward2022-02-14Requires health benefits coverage for buprenorphine and buprenorphine/naloxone for pain treatment without step therapy or fail-first protocols.Introduced, Referred to Assembly Financial Institutions and Insurance Committee
S2143Carry Forward2022-03-07Requires health benefits coverage for buprenorphine and buprenorphine/naloxone for pain treatment without step therapy or fail-first protocols.Introduced in the Senate, Referred to Senate Commerce Committee
S1650Same As2020-02-13Requires health benefits coverage for buprenorphine and buprenorphine/naloxone for pain treatment without step therapy or fail-first protocols.Introduced in the Senate, Referred to Senate Commerce Committee
S4051Carry Over2019-08-23Requires health benefits coverage for buprenorphine and buprenorphine/naloxone for pain treatment without step therapy or fail-first protocols.Introduced in the Senate, Referred to Senate Commerce Committee
A5719Carry Over2019-08-23Requires health benefits coverage for buprenorphine and buprenorphine/naloxone for pain treatment without step therapy or fail-first protocols.Introduced, Referred to Assembly Financial Institutions and Insurance Committee

New Jersey State Sources


feedback